ENOV
Enovis Corporation
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Best Orthopedic Devices Stocks 2026 →
Enovis (ENOV) Stock: Buy, Sell, or Hold?
$28.22
-0.32 (-1.12%)
▼
5d:
+35.09%
30d:
+54.63%
90d:
+14.3%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (19%)
Quality Score
28/100
Position
EXTENDED
30-Day Fair Range
$17.62 – $22.92
Position: EXTENDED
Forward P/E & Valuation
8.1x
STRETCHED
vs 6.3x historical avg
Wall Street Target
$37.83
+34.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$19.83 / $29.89
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: ENOV is 23.1% above its trading range ($22.92). Market expects 8.7% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.43
Based on -0.5% avg growth
INTRINSIC VALUE TODAY
$13.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $28.22, which is considered extended relative to its 30-day fair value range of $17.62 to $22.92. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.1) compared to its historical average (6.3). At these levels, the market is pricing in 8.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $19.83, while resistance sits at $29.89.
Market Sentiment: ENOV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.83 (+34.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $19.83, while resistance sits at $29.89.
Market Sentiment: ENOV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.83 (+34.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.62 -
$22.92
Company Quality Score
28/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
Trading Range & Key Levels
30-Day Trading Range
$17.62 -
$22.92
Current vs Trading Range
EXTENDED
Support Level
$19.83
Resistance Level
$29.89
Current Trend
Downtrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+23.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.1% below Wall St target ($37.83)
- NEUTRAL: PE elevated vs history but 8.7% growth expectation is conservative given 153% recent growth
- WARNING: Composite score 28/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
8.05
Wall Street Target
$37.83
(+34.1%)
Revenue Growth (YoY)
1.8%
Earnings Growth (YoY)
153.1%
Profit Margin
-22.9%
Valuation Premium vs History
+8.7% premium
PE vs Historical
8.1 vs 6.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.7%
(market-implied from PE analysis)
1-Year Target
$30.68
(+9%)
2-Year Target
$33.34
(+18%)
3-Year Target
$36.24
(+28%)
3-Yr Target (if PE normalizes)
(PE: 8→6)
PE COMPRESSION
$28.37
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -5.1%)
$59.57
(+111%)
Base:
(SPY PE: 8.0, Growth: -5.1%)
$24.14
(-15%)
Bear:
(PE: 6.3, Growth: -5.1%)
$18.90
(-33%)
Share ENOV Analysis
Share this live ENOV analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ENOV)
Neutral
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 4, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits shows 100.0% bullish sentiment towards $ENOV with no recent news articles available.
Key Retail Themes:
Bullish sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 10, 2026 9:20 PM ET
Data refreshes hourly during market hours. Next update: 10:20 PM
Data refreshes hourly during market hours. Next update: 10:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
30 analysts |
$112 | 42 HOLD |
|
BSX
Boston Scientific Corp |
BUY
31 analysts |
$50 | 53 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 35 SELL |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$178 | 43 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ENOV Research Pages
